Phenylpropanolamine & risk of hemorrhagic stroke: Final Report of The Hemorrhagic Stroke Project

Download 0.49 Mb. Page 8/10 Date 13.06.2017 Size 0.49 Mb. #20532

Navigate this page:

• 2.03 (p=.237)
• 0.25 (p=.140)

2.61 (p=.132)

3.82

1.05

.043

MEN

	Cases		Controls		Unadjusted	Adjusted Estimates1
	(n=319)		(n=626)		Matched OR	Matched OR	LCL2	p-value
	No.	%	No.	%
No use3	309	96.9%	597	95.4%	--	--	--	--
Current use4	5	1.6%	5	0.8%	2.03 (p=.237)	1.26	0.34	.385
First use5	1	0.3%	1	0.2%	2.00 (p=.556)	2.95	0.24	.241
Not-first use	4	1.2%	4	0.6%	2.06 (p=.285)	0.95	--	.479
Prior use6	1	0.3%	8	1.3%	0.25 (p=.140)	0.25	--	.098

¹Matched odds ratio adjusted for smoking, hypertension, race and education.

²Lower limit of one-sided 95% confidence interval.

³No PPA use in 2-week period before focal time.

⁴Use of any PPA-containing product on index date (ID) before focal time or preceding calendar day.

⁵Current use and no other uses in 2-week period before ID.

⁶Use of any PPA-containing product 2 or 3 calendar days prior to ID.

Appendix E
Analyses Stratified by Sentinel Symptoms: Phenylpropanolamine (PPA) Exposure

and Risk of Hemorrhagic Stroke

NO SENTINEL SYMPTOMS

	Cases		Controls		Unadjusted	Adjusted Estimates1
	(n=548)		(n=1075)		Matched OR	Matched OR	LCL2	p-value
	No.	%	No.	%
No use3	519	94.7%	1022	95.1%	--	--	--	--
Any PPA4	20	3.6%	26	2.4%	1.55 (p=.104)	1.33	0.77	.194
Cough/cold remedy	17	3.1%	25	2.3%	1.35 (p=.221)	1.12	0.64	.371
Appetite suppressant	4	0.7%	1	0.1%	7.96 (p=.046)	12.10	1.39	.029

Directory: ohrms -> dockets
dockets -> Company Product(s) url
dockets -> No Company Product(s) url
dockets -> Panel information package
dockets -> Advisory committee
dockets -> Public Health Impact of Pathogenic Vibrio parahaemolyticus In Raw Oysters
dockets -> Summary minutes of the
dockets -> Droid Sans Fallback

Download 0.49 Mb.

Share with your friends: